Evidence map›Paper›PMID 24792156›Full record

ArticleNucleic acids research2014

XTMS: pathway design in an eXTended metabolic space.

Pablo Carbonell, Pierre Parutto, Joan Herisson, Shashi Bhushan Pandit, Jean-Loup Faulon

Abstract read
In one paragraph

Article in Nucleic acids research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Enzyme annotation for orphan and novel reactions using knowledge of substrate reactive sites.Proceedings of the National Academy of Sciences of the United States of America · 2019
    Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Pablo CarbonellUniversity of Evry, iSSB, F-91000 Evry, France CNRS, iSSB, F-91000 Evry, France jean-loup.faulon@issb.genopole.fr.
Pierre ParuttoUniversity of Evry, iSSB, F-91000 Evry, France CNRS, iSSB, F-91000 Evry, France.
Joan HerissonUniversity of Evry, iSSB, F-91000 Evry, France CNRS, iSSB, F-91000 Evry, France.
Shashi Bhushan PanditIISER Mohali, SAS Nagar, Manauli, PO 140306, Mohali, Punjab, India.
Jean-Loup FaulonUniversity of Evry, iSSB, F-91000 Evry, France CNRS, iSSB, F-91000 Evry, France jean-loup.faulon@issb.genopole.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As metabolic engineering and synthetic biology progress toward reaching the goal of a more sustainable use of biological resources, the need of increasing the number of value-added chemicals that can be produced in industrial organisms becomes more imperative. Exploring, however, the vast possibility of pathways amenable to engineering through heterologous genes expression in a chassis organism is complex and unattainable manually. Here, we present XTMS, a web-based pathway analysis platform available at http://xtms.issb.genopole.fr, which provides full access to the set of pathways that can be imported into a chassis organism such as Escherichia coli through the application of an Extended Metabolic Space modeling framework. The XTMS approach consists on determining the set of biochemical transformations that can potentially be processed in vivo as modeled by molecular signatures, a specific coding system for derivation of reaction rules for metabolic reactions and enumeration of all the corresponding substrates and products. Most promising routes are described in terms of metabolite exchange, maximum allowable pathway yield, toxicity and enzyme efficiency. By answering such critical design points, XTMS not only paves the road toward the rationalization of metabolic engineering, but also opens new processing possibilities for non-natural metabolites and novel enzymatic transformations.

Indexed as

Metabolic EngineeringMetabolic Networks and PathwaysSoftwareEscherichia coliInternet

Identifiers

PMID24792156
PMCPMC4086079

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.